These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 11301850)

  • 1. Novel approaches in the treatment of non-small-cell lung cancer.
    Rosell R; Sánchez JM; Tarón M; O'Brate A; Gutiérrez JL; Monzó M; Felip E; Sánchez JJ; Alberola V
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 6):52-60. PubMed ID: 11301850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.
    Sarries C; Haura EB; Roig B; Taron M; Abad A; Scagliotti G; Rosell R
    Pharmacogenomics; 2002 Nov; 3(6):763-80. PubMed ID: 12437479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer.
    Rosell R; Manegold C; Moran T; Garrido P; Blanco R; Lianes P; Stahel R; Trigo JM; Wei J; Taron M
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S76-82. PubMed ID: 21885003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer.
    Yokomise H; Liu D; Ishikawa S; Go T; Gotoh M; Okuda M; Tarumi S; Kasai Y; Matsuura N
    Anticancer Res; 2013 Dec; 33(12):5597-602. PubMed ID: 24324104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions.
    Bunn PA
    Semin Oncol; 1994 Jun; 21(3 Suppl 6):49-59. PubMed ID: 8052874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
    Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
    Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to the treatment of lung cancer.
    Splinter TA
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-1-S12-5. PubMed ID: 9331110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer.
    Vokes EE; Leopold KA; Herndon J; Green MR
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-42-S8-45. PubMed ID: 9207317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
    Ikeda S; Takabe K; Suzuki K
    Pathol Int; 2009 Dec; 59(12):863-7. PubMed ID: 20021611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New directions in non-small cell lung cancer.
    Gralla RJ
    Semin Oncol; 1990 Aug; 17(4 Suppl 7):14-9. PubMed ID: 2166345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation chemotherapy in multimodality therapy of non-small cell lung cancer.
    Vokes EE
    Front Radiat Ther Oncol; 1992; 26():64-71. PubMed ID: 1324877
    [No Abstract]   [Full Text] [Related]  

  • 15. The treatment of inoperable patients with non-small-cell lung cancer.
    Feld R
    Nihon Kyobu Shikkan Gakkai Zasshi; 1994 Dec; 32 Suppl():19-24. PubMed ID: 7602831
    [No Abstract]   [Full Text] [Related]  

  • 16. Controversies in the nonsurgical treatment of stage III non-small cell lung cancer.
    Hazuka MB; Bunn PA
    Am Rev Respir Dis; 1992 Apr; 145(4 Pt 1):967-77. PubMed ID: 1313216
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recent issues in the treatment of advanced non-small-cell lung cancer].
    Negoro S
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1671-9. PubMed ID: 9757191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of small cell lung cancer].
    Ueoka H; Ohnoshi T
    Gan To Kagaku Ryoho; 1994 Nov; 21(15):2571-7. PubMed ID: 7979415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
    Takeda M; Okamoto I; Hirabayashi N; Kitano M; Nakagawa K
    Lung Cancer; 2011 Jul; 73(1):103-9. PubMed ID: 21111509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative therapy of non-small cell lung cancer: a review of adjuvant and neoadjuvant approaches.
    Friedland DM; Comis RL
    Semin Oncol; 1995 Dec; 22(6):571-81. PubMed ID: 8539633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.